Whole phenotype of patients with systemic sclerosis and sicca manifestations: Comparison with sicca manifestations from other causes.

Autor: Zimmermann F; Department of Internal Medicine, CHU Rennes, University of Rennes 1, Rennes, France; Université de Rennes, CHU Rennes, Inserm, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Rennes, France. Electronic address: francois.zimmermann@chu-rennes.fr., Robin F; Department of Rheumatology, CHU Rennes, University of Rennes 1, Rennes, France; INSERM, Rennes University Hospital, UMR 1241, Institut NuMeCan (Nutrition Metabolisms and Cancer), University Rennes, France., Diot E; Department of Internal Medicine CHRU Tours, Tours, France., Bleuzen A; Medical Imaging, CHRU Tours, Tours, France., Jousse-Joulin S; Rheumatology Department, CHU de Brest, Univ Brest, Inserm, LBAI, UMR1227, Brest, France., de Moreuil C; Department of Internal Medicine CHRU Brest, Brest, France., Belhomme N; Department of Internal Medicine, CHU Rennes, University of Rennes 1, Rennes, France; Université de Rennes, CHU Rennes, Inserm, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Rennes, France., Cazalets C; Department of Internal Medicine, CHU Rennes, University of Rennes 1, Rennes, France., Garlantézec R; University of Rennes, CHU Rennes, Inserm, EHESP, IRSET (Institut de recherche en santé, environnement et tra-ail) - UMR_S 1085, F-35000, Département de Santé Publique, CHRU Rennes, France., Gazzola A; Departement of research and innovation, CHU Rennes, France., Llamas-Gutierrez F; Department of Pathology, CHU Rennes, University of Rennes 1, Rennes, France., Muraz R; Departement of research and innovation, CHU Rennes, France., Perlat A; Department of Internal Medicine, CHU Rennes, University of Rennes 1, Rennes, France., Coiffier G; Department of Internal Medicine, CHU Rennes, University of Rennes 1, Rennes, France; Department of Rheumatology, CH Dinan, Dinan, France., Lescoat A; Department of Internal Medicine, CHU Rennes, University of Rennes 1, Rennes, France; Université de Rennes, CHU Rennes, Inserm, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Rennes, France.
Jazyk: angličtina
Zdroj: Seminars in arthritis and rheumatism [Semin Arthritis Rheum] 2024 Oct; Vol. 68, pp. 152480. Date of Electronic Publication: 2024 Jul 04.
DOI: 10.1016/j.semarthrit.2024.152480
Abstrakt: Introduction & Objectives: This study aimed to characterize the whole phenotype of Systemic sclerosis (SSc) patients with sicca symptoms, using major salivary glands Ultrasound (SGUS) parameters, minor salivary glands biopsies (mSGB) and clinical findings, and to compare these characteristics with those from patients with Sjogren's Disease (SjD), and patients with sicca manifestations from other causes.
Methods: Sixty SSc patients fulfilling the 2013 ACR/EULAR classification criteria and with subjective self-declared sicca symptoms were consecutively recruited and had SGUS and mSGB. Fifteen SSc patients without subjective sicca symptoms and 65 patients with sicca symptoms from other causes (including 37 SjD with no SSc).
Results: SSc patients with subjective sicca symptoms had frequent objective clinical (up to 83 %), histological (44 % of Focus score≥1/ mm2) and US anomalies (63 % of OMERACT ≥2). 53 % patients without subjective clinical complaint also had abnormal objective tests, suggesting the existence of a sub clinical involvement of salivary glands in SSc. SjD-SSc patients had more severe glandular involvement as compared to patients with isolated SjD and isolated Sicca-SSc patients (70%, 48,6 % and 38% of patients with OMERACT ≥2 respectively) suggesting additive impact of both diseases on glandular physiology and structure.
Conclusion: SjD-SSc overlap have more severe sicca features as compared to isolated sicca-SSc and isolated SjD, suggesting a specific impact of SSc on salivary gland physiology. Further translational studies are needed to identify the underlying pathways that could serve as therapeutic targets.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr Antoinette PERLAT declares 1 Oral presentation , with paiement on Behçet disease 04.24 ( AMGEN) Dr Nicolas BELHOMME declares for past 36 months consulting fees (AstraZeneca) and payment or honoraria for lectures (Astrazeneca, CHUGAI Pharma GSK and LeoPharma)
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: